

EMA/CO Therapy (Etoposide, Methotrexate, DACTINomycin, Cyclophosphamide, vinCRISine)

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement Status
Treatment of high risk gestational trophoblastic neoplasia (GTN) (FIGO score ≥ 7)	D39	00248a	Hospital
Treatment of patients with low risk GTN who have not responded or have relapsed from sequential single-agent treatment single agent chemotherapy (methotrexate and DACTINomycin)	D39	00248b	Hospital
Treatment of patients with low-risk GTN who have not responded to methotrexate with a hCG $>1,000$ IU/L	D30	00248c	Hospital

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

Treatment with EMA (etoposide, methotrexate, DACTINomycin) alternates every week with vinCRISine and cyclophosphamide and is administered continuously until hCG values fall below the upper limit of normal or unacceptable toxicity develops.

Low risk GTN: Treatment should be continued until hCG is normal and then usually for three further courses to eliminate any residual tumour cells and to minimise the chances of relapse.

High risk GTN: Treatment should be continued for 3 cycles (6 weeks) after normalisation of hCG values. This may be extended to 4 cycles (8 weeks) in patients with poor prognostic features such as liver metastases with or without brain metastases.

- Etoposide can be omitted once HCG levels fall below the upper limit of normal to reduce the risk of AML/MDS
- Steroid dosing should be minimized to reduce the risk of avascular necrosis
- G-CSF therapy is often required to maintain dose intensity of this regimen

NCCP Regimen: EMA/CO Therapy	Published: 01/02/2016 Review: 06/01/2026	Version number: 3
Tumour Group: Gynaecology NCCP Regimen Code: 00248	ISMO Contributor: Prof Macon Keane, Prof Seamus O'Reilly	Page 1 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Admin. Order	Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	1,2	DACTINomycin	0.5mg	IV Bolus	n/a	See above for details
2	1,2	Etoposide	100mg/m ²	IV	1000ml 0.9% NaCl over 60mins*	See above for details
3	1	Methotrexate	300mg/m ²	IV	1000ml 0.9% NaCl over 12 hours	See above for details
1	2, 3	Folinic Acid	15mg	PO	Every 12 hours for 4 doses (to be started 24hrs after start of methotrexate)	See above for details
1	8	**vinCRISine	0.8mg/m ² (cap dose at 2mg)	IV infusion	50mL 0.9% NaCl minibag over 15 minutes.	See above for details
2	8	Cyclophosphamide	600mg/m ²	IV	250ml 0.9% NaCl over 30minutes	See above for details
*Hypotension following rapid IV administration has been reported. Longer infusion times may be required based on the patient's tolerance						
**VinCRISine is a neurotoxic chemotherapeutic agent. Refer to NCCP Guidance on the Safe Use of Neurotoxic drugs (including Vinca Alkaloids) in the treatment of cancer						

ELIGIBILITY:

- Indications as above

EXCLUSIONS:

- Hypersensitivity to etoposide, methotrexate, folinic acid, DACTINomycin, vinCRISine, cyclophosphamide or any of the excipients.

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

TESTS:

Baseline tests:

- FBC, renal and liver profile
- human chorionic gonadotropin (hCG)

NCCP Regimen: EMA/CO Therapy	Published: 01/02/2016 Review: 06/01/2026	Version number: 3
Tumour Group: Gynaecology NCCP Regimen Code: 00248	ISMO Contributor: Prof Macon Keane, Prof Seamus O'Reilly	Page 2 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Regular tests:

- FBC, renal and liver profile prior to each cycle.
- Serum hCG/blood should be done on day one of each cycle or more frequently if required.
 - After remission is achieved serum hCG should be measured fortnightly for six months then monthly for a further six months and then every two months for two years.
- Follow-up for at least 5 years may be considered for those at highest risk.

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.
- Due to the curative aim of treatment, dose modifications should be avoided and made only made after discussion with the Consultant in charge of treatment.
- G-CSF support may be considered.
- In general treatment may proceed if neutrophils $> 1.0 \times 10^9/L$ and platelets $> 75 \times 10^9/L$.
- To avoid extended intervals between courses caused by myelosuppression, it may occasionally be necessary to reduce the EMA by omitting the day 2 doses of etoposide and DACTINomycin. This problem is usually overcome with G-CSF and increased frequency (four doses daily) and duration (up to 4 days) of folinic acid rescue. Rescue should start 24 h after start of methotrexate infusion (3).

NCCP Regimen: EMA/CO Therapy	Published: 01/02/2016 Review: 06/01/2026	Version number: 3
Tumour Group: Gynaecology NCCP Regimen Code: 00248	ISMO Contributor: Prof Macon Keane, Prof Seamus O'Reilly	Page 3 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Renal and Hepatic Impairment:

Table 1: Dose modifications in renal and hepatic impairment

Drug	Renal Impairment		Hepatic Impairment			
	CrCl (ml/min)	Dose	Bilirubin (micromol/L)		AST	Dose
Etoposide	>50	100%	26-51	or	60-180	50%
	15-50	75%	>51	or	>180	Clinical decision
	<15	50%				
	Subsequent doses should be based on clinical responses					
Methotrexate	CrCl (ml/min)	Dose	Bilirubin (micromol/L)		AST (Units)	Dose
	>80	100%	<50	and	<180	100%
	60-80	65%	51-85	or	>180	75%
	45-60	50%	>85			Contraindicated
	30-45	Clinical decision				
	<30	Contraindicated				
DACTINomycin	Clinical decision – unlikely to require a reduction.		Consider dose reduction in severe hepatic disease.			
vinCRISTine	No dose reduction necessary		Bilirubin (micromol/L)		AST/ALT (Units)	Dose
			26-51	or	60-180	50%
			>51	and	Normal	50%
			>51	and	>180	Omit
Cyclophosphamide	CrCl (ml/min)	Dose	Not recommended in patients with a bilirubin >17micromol/L or serum transaminases or ALP more than 2-3 x upper limit of normal. In all such cases doses should be reduced			
	>20	100%				
	10-20	75%				
	<10	50%				
	Clinical decision-Consider whether patient is being treated with high dose treatment					

Management of adverse events:

Table 2: Dose Modification for Adverse Events

Adverse reactions	Recommended dose modification
Peripheral neuropathy Grade 2 Grade ≥3	Reduce vinCRISTine dose by 25%. If persists, reduce vinCRISTine by 50%. Omit vinCRISTine.
Mucositis and stomatitis or Diarrhoea Grade 3:1 st occurrence:	Delay treatment until toxicity has resolved to Grade 1 or less and reduce the dose for subsequent cycles as follow: Reduce DACTINomycin, etoposide, methotrexate,

NCCP Regimen: EMA/CO Therapy	Published: 01/02/2016 Review: 06/01/2026	Version number: 3
Tumour Group: Gynaecology NCCP Regimen Code: 00248	ISMO Contributor: Prof Macon Keane, Prof Seamus O'Reilly	Page 4 of 8
The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer <i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i>		

2 nd occurrence:	vinCRIS ^t ine and cyclophosphamide by 25%.
Grade 4:1 st occurrence:	Reduce DACTINomycin, etoposide, methotrexate, vinCRIS ^t ine and cyclophosphamide by 50%.
2 nd occurrence:	Delay treatment until toxicity has resolved to Grade 1 or less and reduce the dose for subsequent cycles as follow: Reduce DACTINomycin, etoposide, methotrexate, vinCRIS ^t ine and cyclophosphamide by 50%.
2 nd occurrence:	Stop treatment.
Third space fluids (ascites, pleural effusions, very large ovarian cysts)	Hold methotrexate until recovery.
Malignant lymphoma	Discontinue.

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

DACTINomycin	Moderate	(Refer to local policy).
Etoposide	Low	(Refer to local policy).
Methotrexate	Moderate	(Refer to local policy).
vinCRIS^tine	Minimal	(Refer to local policy).
Cyclophosphamide	Moderate	(Refer to local policy).

PREMEDICATIONS: Not usually required

OTHER SUPPORTIVE CARE:

G-CSF may be used to mitigate the risk of haematological toxicities.

Prophylactic laxatives to prevent constipation related to the use of vinca alkaloids.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS:

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately. G-CSF will likely be needed to maintain white count.
- **Extravasation:** DACTINomycin and vinCRIS^tine cause pain and tissue necrosis if extravasated.

Etoposide

- **Hypersensitivity:** There is a high risk of hypersensitivity reactions with etoposide. Monitor infusion of etoposide for the first 15 minutes for signs of hypotension.

Methotrexate

- **Respiratory system:** Acute or chronic interstitial pneumonitis, often associated with blood

NCCP Regimen: EMA/CO Therapy	Published: 01/02/2016 Review: 06/01/2026	Version number: 3
Tumour Group: Gynaecology NCCP Regimen Code: 00248	ISMO Contributor: Prof Macon Keane, Prof Seamus O'Reilly	Page 5 of 8

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens

eosinophilia may occur and deaths have been reported. Symptoms typically include dyspnoea, cough (especially a dry non-productive cough) and fever for which patients should be monitored at each follow-up visit. Patients should be informed of the risk of pneumonitis and advised to contact their doctor immediately should they develop persistent cough or dyspnoea.

- **Hepatotoxicity:** Methotrexate-induced hepatotoxicity can be seen with both high and low-dose methotrexate, and can be life-threatening. Increased serum aminotransferases and less commonly hyperbilirubinemia is seen more often in high-dose methotrexate. The liver enzymes can increase with each cycle, and usually return to pre-treatment levels once methotrexate has been discontinued for 1 month. Cirrhosis and fibrosis are more often seen with chronic low-dose methotrexate. Patients should be warned to avoid alcohol, prescription medications or herbal supplements that may increase risk of hepatotoxicity.
- **Pleural effusions and ascites:** These should be drained prior to initiation of methotrexate treatment.

vinCRISTine

- **Neuropathy:** VinCRISTine may cause peripheral neuropathy which is dose related and cumulative, requiring monitoring before each dose is administered. The presence of pre-existing neuropathies or previous treatment with other neurotoxic drugs may increase risk of peripheral neuropathy. Patients with mild peripheral neuropathy can usually continue to receive full doses of vinCRISTine, but when symptoms increase in severity and interfere with neurologic function, dose reduction or discontinuation of the drug may be necessary. The natural history following discontinuation of treatment is gradual improvement, which may take up to several months. A routine prophylactic regimen against constipation is recommended for all patients receiving vinCRISTine sulphate. Paralytic ileus may occur. The ileus will reverse itself upon temporary discontinuance of vinCRISTine and with symptomatic care.

DRUG INTERACTIONS:

- CYP3A4 inducers may increase the clearance of etoposide and vinCRISTine.
- CYP3A4 inhibitors may decrease the clearance of etoposide and vinCRISTine.
- NSAIDs may decrease the clearance of methotrexate by decreasing its renal perfusion and tubular secretion thus increasing its toxicity.
- Sulphonamides and penicillins may displace bound methotrexate from plasma protein increasing serum methotrexate levels and its toxicity.
- Concomitant administration of drugs that cause folate deficiency may lead to increased methotrexate toxicity.
- Ciprofloxacin may inhibit renal tubular transport of methotrexate, increasing serum methotrexate levels and its toxicity.
- Probenecid may inhibit renal excretion of methotrexate, increasing serum methotrexate levels and its toxicity.
- Current drug interaction databases should be consulted for more information.

ATC CODE:

Etoposide

L01CB01

NCCP Regimen: EMA/CO Therapy	Published: 01/02/2016 Review: 06/01/2026	Version number: 3
Tumour Group: Gynaecology NCCP Regimen Code: 00248	ISMO Contributor: Prof Macon Keane, Prof Seamus O'Reilly	Page 6 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Methotrexate	L01BA01
DACTINomycin	L01DA01
Folinic Acid	V03AF03
vinCRISine	L01CA02
Cyclophosphamide	L01AA01

REFERENCES:

1. Newlands ES, Bagshawe KD et al. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989. Br J Obstet Gynaecol 1991 98(6):550-7
2. Bower M, Newlands ES et al. EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients J Clin Oncol 1997;15(7):2636-43
3. Seckl et al. Gestational trophoblastic disease. Lancet 2010; 376:717-29.
4. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network. Available at <http://londoncancer.org/media/65600/renal-impairment-dosage-adjustment-for-cytotoxics.pdf>
5. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009; North London Cancer Network. Available at <http://londoncancer.org/media/65594/hepatic-impairment-dosage-adjustment-for-cytotoxics.pdf>
6. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V2 2019. Available at: <https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>
7. Etoposide 20 mg/ml Concentrate for Solution for Infusion Summary of Product Characteristics. Accessed Oct 2020 Available at https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2059-036-001_29072019103821.pdf
8. Methotrexate 1g/10ml Summary of Product Characteristics. Accessed Oct 2020. https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA0822-206-006_23092020105544.pdf
9. Dactinomycin (COSMEGEN® LYOVAC). Summary of Product Characteristics. Accessed Oct 2020 Available at <https://www.medicines.org.uk/emc/product/5360>
10. Vincristine Summary of Product Characteristics. Accessed October 2020 Available at: <https://www.medicines.ie/medicines/vincristine-sulphate-1-mg-ml-solution-for-injection-or-infusion-34195/smpc>
11. Cyclophosphamide Summary of Product Characteristics. Accessed Oct 2020. Available at: https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2299-027-002_21122018112109.pdf

NCCP Regimen: EMA/CO Therapy	Published: 01/02/2016 Review: 06/01/2026	Version number: 3
Tumour Group: Gynaecology NCCP Regimen Code: 00248	ISMO Contributor: Prof Macon Keane, Prof Seamus O'Reilly	Page 7 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		

Version	Date	Amendment	Approved By
1	01/02/2016		Prof Maccon Keane
2	07/02/2018	Updated with new NCCP regimen template and updated dosing in renal and hepatic impairment	Prof Maccon Keane
3	06/01/2021	Indication for use updated, treatment wording updated. Updated exclusion criteria. Updated hCG monitoring requirements. Standardisation of cyclophosphamide infusion volume and recommendations in hepatic impairment Updated emetogenic potential and adverse events section.	Prof Seamus O'Reilly

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

NCCP Regimen: EMA/CO Therapy	Published: 01/02/2016 Review: 06/01/2026	Version number: 3
Tumour Group: Gynaecology NCCP Regimen Code: 00248	ISMO Contributor: Prof Macon Keane, Prof Seamus O'Reilly	Page 8 of 8
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoregimens</i></p>		